Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yibing Lu

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Arthritis & Rheumatology (Hoboken, N.J.)|May 26, 2025
Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in ChinaJia Sun, Yu Wang, Yongjing Cheng, et al.
Frontiers in Microbiology|October 3, 2022
Prevalence and risk factors of carbapenem-resistant <i>Enterobacterales</i> positivity by active screening in intensive care units in the Henan Province of China: A multi-center cross-sectional studyBo Guo, Ziqi Guo, Huifeng Zhang, et al.
The Lancet. Diabetes & Endocrinology|June 24, 2025
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLinong Ji, Leili Gao, Haibo Xue, et al.
Nature Communications|January 7, 2026
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trialDalong Zhu, Weimin Wang, Guoyu Tong, et al.
Nature Medicine|May 13, 2022
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialDalong Zhu, Xiaoying Li, Jianhua Ma, et al.
Diabetologia|November 21, 2025
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trialDalong Zhu, Jianhua Ma, Weimin Wang, et al.
Nature Medicine|May 13, 2022
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialWenying Yang, Dalong Zhu, Shenglian Gan, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Arthritis & Rheumatology (Hoboken, N.J.)|May 26, 2025
Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in ChinaJia Sun, Yu Wang, Yongjing Cheng, et al.
Frontiers in Microbiology|October 3, 2022
Prevalence and risk factors of carbapenem-resistant <i>Enterobacterales</i> positivity by active screening in intensive care units in the Henan Province of China: A multi-center cross-sectional studyBo Guo, Ziqi Guo, Huifeng Zhang, et al.
The Lancet. Diabetes & Endocrinology|June 24, 2025
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLinong Ji, Leili Gao, Haibo Xue, et al.
Nature Communications|January 7, 2026
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trialDalong Zhu, Weimin Wang, Guoyu Tong, et al.
Nature Medicine|May 13, 2022
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialDalong Zhu, Xiaoying Li, Jianhua Ma, et al.
Diabetologia|November 21, 2025
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trialDalong Zhu, Jianhua Ma, Weimin Wang, et al.
Nature Medicine|May 13, 2022
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialWenying Yang, Dalong Zhu, Shenglian Gan, et al.
Pageof 6